Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:NVO

Novo-Nordisk (NVO)

43.11
-0.08 (0.19%)
as of Jun 18, 2026, 11:38:14 pm Market Open.
88 watching
0
BUY
Insulin maker out of Denmark. Good pipeline and good patent protection. Diabetic patients will double over the next 10 to 20 years.
BUY
Largest insulin manufacturer in the world. Also makes a haemophiliac medicine that provides clotting during surgery. About to get FDA approval for an application for stroke victims and gunshot wounds.
PAST TOP PICK
(A Top Pick Aug 3/05. Up 23%.) Added more salespeople in the US. Sales on the insulin side are growing. Still a lot of growth coming.
TOP PICK
His favourite pharmaceutical. 1.5% dividend and dividend growth has been 20% over the last 5 years. Largest supplier of insulin in the world. Rate of diabetes continues to rise. Cheap at this price.
BUY
Past Top pick. Insulin demain is growing over the next 20 years. It's still a long term investment.
TOP PICK
Manufactures insulin. Human insulin is in huge demand and they control the market. Good earnings last quarter. Good price.
TOP PICK
The growth in cases of diabetes in the next 20 years is expected to double from 3 to 6 hundred million globally. The stock had fallen from $58 to the low $50's because their drug was going to be delayed. Stock is now getting interesting.
PAST TOP PICK
(A top pick Dec 1/03. Up 30%.) The cases of diabetics is expected to double.
TOP PICK
In pharmaceuticals, they devote most money per revenue into R&D. Demographically, feels that China and India will be strong future markets.
TOP PICK
Takeover target. Diabetes is growing. Expects 10/15% growth over time.
BUY
Great company. Will do well.
TOP PICK
Trading at FMV. 33% growth in diabetes.
TOP PICK
Just split. Growing 40% in sales. Growth is in the 30/40% range.
BUY
Bullet proof portfolio-mid caps (35%)
TOP PICK
Good earnings. Growing at 50% a year.
Showing 106 to 120 of 121 entries